{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:34:26Z","timestamp":1787751266935,"version":"build-2784847793"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aims to assess the predictive capability of cylindrical Tumor Growth Rate (cTGR) in the prediction of early progression of well-differentiated gastro-entero-pancreatic tumours after Radio Ligand Therapy (RLT), compared to the conventional TGR. Fifty-eight patients were included and three CT scans per patient were collected at baseline, during RLT, and follow-up. RLT response, evaluated at follow-up according to RECIST 1.1, was calculated as a percentage variation of lesion diameters over time (continuous values) and as four different RECIST classes. TGR between baseline and interim CT was computed using both conventional (approximating lesion volume to a sphere) and cylindrical (called cTGR, approximating lesion volume to an elliptical cylinder) formulations. Receiver Operating Characteristic (ROC) curves were employed for Progressive Disease class prediction, revealing that cTGR outperformed conventional TGR (area under the ROC equal to 1.00 and 0.92, respectively). Multivariate analysis confirmed the superiority of cTGR in predicting continuous RLT response, with a higher coefficient for cTGR (1.56) compared to the conventional one (1.45). This study serves as a proof of concept, paving the way for future clinical trials to incorporate cTGR as a valuable tool for assessing RLT response.<\/jats:p>","DOI":"10.1038\/s41598-024-66668-9","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T09:01:58Z","timestamp":1720515718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cylindrical TGR as early radiological predictor of RLT progression in GEPNETs: a proof of concept"],"prefix":"10.1038","volume":"14","author":[{"given":"Federica","family":"Scalorbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico Matteo","family":"Garanzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Calareso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Marzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Di Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Argiroffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Baccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pusceddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Marchian\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Maccauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"issue":"4","key":"66668_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","volume":"23","author":"S Das","year":"2021","unstructured":"Das, S. & Dasari, A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: Are there global differences?. Curr. Oncol. Rep. 23(4), 43. https:\/\/doi.org\/10.1007\/s11912-021-01029-7 (2021).","journal-title":"Curr. Oncol. Rep."},{"issue":"10","key":"66668_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari, A. et al. Trends in the Incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 3(10), 1335. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589 (2017).","journal-title":"JAMA Oncol."},{"issue":"2","key":"66668_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12020-017-1273-x","volume":"58","author":"E Leoncini","year":"2017","unstructured":"Leoncini, E. et al. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine 58(2), 368\u2013379. https:\/\/doi.org\/10.1007\/s12020-017-1273-x (2017).","journal-title":"Endocrine"},{"key":"66668_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100510","volume":"23","author":"BE White","year":"2022","unstructured":"White, B. E. et al. Incidence and survival of neuroendocrine neoplasia in England 1995\u20132018: A retrospective, population-based study. Lancet Reg. Health\u2013Europe. 23, 100510. https:\/\/doi.org\/10.1016\/j.lanepe.2022.100510 (2022).","journal-title":"Lancet Reg. Health\u2013Europe."},{"key":"66668_CR5","unstructured":"WHO, IARC, eds. Digestive System Tumours. 5th ed. International agency for research on cancer; 2019."},{"issue":"1","key":"66668_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi, G. et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr. Pathol. 33(1), 115\u2013154. https:\/\/doi.org\/10.1007\/s12022-022-09708-2 (2022).","journal-title":"Endocr. Pathol."},{"issue":"6","key":"66668_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3322\/caac.21493","volume":"68","author":"M Cives","year":"2018","unstructured":"Cives, M. & Strosberg, J. R. Gastroenteropancreatic neuroendocrine tumors. CA A Cancer J. Clin. 68(6), 471\u2013487. https:\/\/doi.org\/10.3322\/caac.21493 (2018).","journal-title":"CA A Cancer J. Clin."},{"issue":"7","key":"66668_CR8","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel, M. et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31(7), 844\u2013860. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.304 (2020).","journal-title":"Ann. Oncol."},{"key":"66668_CR9","unstructured":"AGENZIA ITALIANA DEL FARMACO | DETERMINA 11 marzo 2019. https:\/\/www.aifa.gov.it\/documents\/20142\/847786\/Determina_501-2019_Lutathera.pdf"},{"key":"66668_CR10","unstructured":"Lutathera | European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lutathera"},{"issue":"2","key":"66668_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg, J. et al. Phase 3 trial of 177 Lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376(2), 125\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1607427 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"66668_CR12","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg, J. R. et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): Final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 22(12), 1752\u20131763. https:\/\/doi.org\/10.1016\/S1470-2045(21)00572-6 (2021).","journal-title":"Lancet Oncol."},{"issue":"2","key":"66668_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 11). Eur. J. Cancer 45(2), 228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026 (2009).","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"66668_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI: J. Natl. Cancer Inst. 92(3), 205\u2013216. https:\/\/doi.org\/10.1093\/jnci\/92.3.205 (2000).","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"4","key":"66668_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000342270","volume":"96","author":"A Sundin","year":"2012","unstructured":"Sundin, A. & Rockall, A. Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: The challenges ahead. Neuroendocrinology 96(4), 261\u2013271. https:\/\/doi.org\/10.1159\/000342270 (2012).","journal-title":"Neuroendocrinology"},{"issue":"2","key":"66668_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nrendo.2013.246","volume":"10","author":"M Van Essen","year":"2014","unstructured":"Van Essen, M., Sundin, A., Krenning, E. P. & Kwekkeboom, D. J. Neuroendocrine tumours: The role of imaging for diagnosis and therapy. Nat. Rev. Endocrinol. 10(2), 102\u2013114. https:\/\/doi.org\/10.1038\/nrendo.2013.246 (2014).","journal-title":"Nat. Rev. Endocrinol."},{"issue":"11","key":"66668_CR17","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/17474124.2019.1685381","volume":"13","author":"S Das","year":"2019","unstructured":"Das, S., Al-Toubah, T., El-Haddad, G. & Strosberg, J. 177 Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev. Gastroenterol. Hepatol. 13(11), 1023\u20131031. https:\/\/doi.org\/10.1080\/17474124.2019.1685381 (2019).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"66668_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","volume":"105","author":"RJ Hicks","year":"2017","unstructured":"Hicks, R. J. et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues. Neuroendocrinology 105(3), 295\u2013309. https:\/\/doi.org\/10.1159\/000475526 (2017).","journal-title":"Neuroendocrinology"},{"issue":"13","key":"66668_CR19","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom, D. J. et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr 3 ] octreotate: Toxicity, efficacy, and survival. JCO 26(13), 2124\u20132130. https:\/\/doi.org\/10.1200\/JCO.2007.15.2553 (2008).","journal-title":"JCO"},{"key":"66668_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210803","author":"US Choi","year":"2019","unstructured":"Choi, U. S., Kawaguchi, H., Matsuoka, Y., Kober, T. & Kida, I. Brain tissue segmentation based on MP2RAGE multi-contrast images in 7 T MRI. PLoS One https:\/\/doi.org\/10.1371\/journal.pone.0210803 (2019).","journal-title":"PLoS One"},{"issue":"1","key":"66668_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40644-020-00335-w","volume":"20","author":"DMV Huizing","year":"2020","unstructured":"Huizing, D. M. V. et al. Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy. Cancer Imaging 20(1), 57. https:\/\/doi.org\/10.1186\/s40644-020-00335-w (2020).","journal-title":"Cancer Imaging"},{"issue":"1","key":"66668_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12885-017-3150-7","volume":"17","author":"Y Luo","year":"2017","unstructured":"Luo, Y. et al. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?. BMC Cancer 17(1), 154. https:\/\/doi.org\/10.1186\/s12885-017-3150-7 (2017).","journal-title":"BMC Cancer"},{"issue":"7","key":"66668_CR23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41416-019-0558-7","volume":"121","author":"MP Solis-Hernandez","year":"2019","unstructured":"Solis-Hernandez, M. P. et al. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). Br. J. Cancer 121(7), 537\u2013544. https:\/\/doi.org\/10.1038\/s41416-019-0558-7 (2019).","journal-title":"Br. J. Cancer"},{"issue":"3","key":"66668_CR24","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00261-021-03393-1","volume":"47","author":"MJC Van Treijen","year":"2022","unstructured":"Van Treijen, M. J. C. et al. Defining disease status in gastroenteropancreatic neuroendocrine tumors: Choi-criteria or RECIST?. Abdom. Radiol. 47(3), 1071\u20131081. https:\/\/doi.org\/10.1007\/s00261-021-03393-1 (2022).","journal-title":"Abdom. Radiol."},{"issue":"1\u20132","key":"66668_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000090026","volume":"6","author":"M Rodallec","year":"2006","unstructured":"Rodallec, M. et al. Endocrine pancreatic tumours and helical CT: Contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 6(1\u20132), 77\u201385. https:\/\/doi.org\/10.1159\/000090026 (2006).","journal-title":"Pancreatology"},{"issue":"1","key":"66668_CR26","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1158\/1078-0432.CCR-13-2098","volume":"20","author":"C Fert\u00e9","year":"2014","unstructured":"Fert\u00e9, C. et al. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin. Cancer Res. 20(1), 246\u2013252. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2098 (2014).","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"66668_CR27","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.2214\/AJR.09.3456","volume":"194","author":"AD Smith","year":"2010","unstructured":"Smith, A. D., Shah, S. N., Rini, B. I., Lieber, M. L. & Remer, E. M. Morphology, attenuation, size, and structure (MASS) criteria: Assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. Am. J. Roentgenol. 194(6), 1470\u20131478. https:\/\/doi.org\/10.2214\/AJR.09.3456 (2010).","journal-title":"Am. J. Roentgenol."},{"issue":"8","key":"66668_CR28","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1158\/1078-0432.CCR-11-2275","volume":"18","author":"WD Stein","year":"2012","unstructured":"Stein, W. D. et al. Analyzing the pivotal trial that compared sunitinib and IFN-\u03b1 in renal cell carcinoma, using a method that assesses tumor regression and growth. Clin. Cancer Res. 18(8), 2374\u20132381. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2275 (2012).","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"66668_CR29","doi-asserted-by":"publisher","first-page":"R105","DOI":"10.1530\/ERC-13-0365","volume":"21","author":"L De Mestier","year":"2014","unstructured":"De Mestier, L. et al. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: State of the art. Endocr.-Relat. Cancer 21(3), R105\u2013R120. https:\/\/doi.org\/10.1530\/ERC-13-0365 (2014).","journal-title":"Endocr.-Relat. Cancer"},{"issue":"9","key":"66668_CR30","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1159\/000510445","volume":"111","author":"C Dromain","year":"2021","unstructured":"Dromain, C. et al. Tumor growth rate to predict the outcome of patients with neuroendocrine tumors: Performance and sources of variability. Neuroendocrinology 111(9), 831\u2013839. https:\/\/doi.org\/10.1159\/000510445 (2021).","journal-title":"Neuroendocrinology"},{"issue":"11","key":"66668_CR31","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1634\/theoncologist.2018-0672","volume":"24","author":"A Lamarca","year":"2019","unstructured":"Lamarca, A. et al. Value of tumor growth rate (TGR) as an early biomarker predictor of patients\u2019 outcome in neuroendocrine tumors (NET)\u2014the GREPONET study. Oncologist. 24(11), e1082\u2013e1090. https:\/\/doi.org\/10.1634\/theoncologist.2018-0672 (2019).","journal-title":"Oncologist."},{"issue":"22","key":"66668_CR32","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1158\/1078-0432.CCR-19-0963","volume":"25","author":"A Lamarca","year":"2019","unstructured":"Lamarca, A. et al. Tumor growth rate as a validated early radiological biomarker able to reflect treatment-induced changes in neuroendocrine tumors: The GREPONET-2 study. Clin. Cancer Res. 25(22), 6692\u20136699. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0963 (2019).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"66668_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12885-018-5257-x","volume":"19","author":"C Dromain","year":"2019","unstructured":"Dromain, C. et al. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors. BMC Cancer 19(1), 66. https:\/\/doi.org\/10.1186\/s12885-018-5257-x (2019).","journal-title":"BMC Cancer"},{"issue":"4","key":"66668_CR34","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1530\/EC-21-0027","volume":"10","author":"OJ Pettersson","year":"2021","unstructured":"Pettersson, O. J., Fr\u00f6ss-Baron, K., Crona, J. & Sundin, A. Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE. Endocr. Connect. 10(4), 422\u2013431. https:\/\/doi.org\/10.1530\/EC-21-0027 (2021).","journal-title":"Endocr. Connect."},{"issue":"4","key":"66668_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13260","volume":"35","author":"SJ Wang","year":"2023","unstructured":"Wang, S. J. et al. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time. J. Neuroendocrinol. 35(4), e13260. https:\/\/doi.org\/10.1111\/jne.13260 (2023).","journal-title":"J. Neuroendocrinol."},{"key":"66668_CR36","first-page":"988","volume":"76","author":"VP Collins","year":"1956","unstructured":"Collins, V. P. Observations on growth rates of human tumors. AJR. 76, 988\u20131000 (1956).","journal-title":"AJR."},{"issue":"5","key":"66668_CR37","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1086\/623964","volume":"40","author":"H Wadell","year":"1932","unstructured":"Wadell, H. Volume, shape, and roundness of rock particles. J. Geol. 40(5), 443\u2013451. https:\/\/doi.org\/10.1086\/623964 (1932).","journal-title":"J. Geol."},{"key":"66668_CR38","doi-asserted-by":"crossref","unstructured":"Akaike, H. Information theory and an extension of the maximum likelihood principle. In: Selected Papers of Hirotugu Akaike. Springer; 1998:199\u2013213.","DOI":"10.1007\/978-1-4612-1694-0_15"},{"key":"66668_CR39","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176344136","author":"G Schwarz","year":"1978","unstructured":"Schwarz, G. Estimating the dimension of a model. Ann. Statist. https:\/\/doi.org\/10.1214\/aos\/1176344136 (1978).","journal-title":"Ann. Statist."},{"issue":"1","key":"66668_CR40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden, W. J. Index for rating diagnostic tests. Cancer 3(1), 32\u201335. https:\/\/doi.org\/10.1002\/1097-0142(1950)3:1%3c32::AID-CNCR2820030106%3e3.0.CO;2-3 (1950).","journal-title":"Cancer"},{"issue":"10","key":"66668_CR41","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1007\/s00259-020-04712-2","volume":"47","author":"V Prasad","year":"2020","unstructured":"Prasad, V. et al. Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: A need for standardised practice. Eur. J. Nucl. Med. Mol. Imaging 47(10), 2358\u20132371. https:\/\/doi.org\/10.1007\/s00259-020-04712-2 (2020).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"66668_CR42","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin, M. E. et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Eng. J. Med. 371(3), 224\u2013233 (2014).","journal-title":"N. Eng. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66668-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66668-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66668-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T09:03:29Z","timestamp":1720515809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66668-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["66668"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-66668-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"4 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Federica Scalorbi, Dr. Marco Maccauro, and Dr. Sara Pusceddu received honoraria as consultants and speakers from AAA, outside the submitted work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15782"}}